PT  - JOURNAL ARTICLE
AU  - Richard Carr III
AU  - Cynthia Koziol-White
AU  - Jie Zhang
AU  - Hong Lam
AU  - Steven S. An
AU  - Gregory G. Tall
AU  - Reynold A. Panettieri, Jr.
AU  - Jeffrey L. Benovic
TI  - Interdicting G<sub>q</sub> Activation in Airway Disease by Receptor-Dependent and Receptor-Independent Mechanisms
AID  - 10.1124/mol.115.100339
DP  - 2016 Jan 01
TA  - Molecular Pharmacology
PG  - 94--104
VI  - 89
IP  - 1
4099  - http://molpharm.aspetjournals.org/content/89/1/94.short
4100  - http://molpharm.aspetjournals.org/content/89/1/94.full
SO  - Mol Pharmacol2016 Jan 01; 89
AB  - Gαqβγ heterotrimer (Gq), an important mediator in the pathology of airway disease, plays a central role in bronchoconstriction and airway remodeling, including airway smooth muscle growth and inflammation. Current therapeutic strategies to treat airway disease include the use of muscarinic and leukotriene receptor antagonists; however, these pharmaceuticals demonstrate a limited clinical efficacy as multiple Gq-coupled receptor subtypes contribute to these pathologies. Thus, broadly inhibiting the activation of Gq may be an advantageous therapeutic approach. Here, we investigated the effects of broadly inhibiting Gq activation in vitro and ex vivo using receptor-dependent and receptor-independent strategies. P4pal-10 is a protease activated receptor 4–derived pepducin that exhibits efficacy toward multiple Gq-coupled receptors. Mechanistic studies demonstrated that P4pal-10 selectively inhibits all G protein coupling to several Gq-coupled receptors, including protease activated receptor 1, muscarinic acetylcholine M3, and histamine H1 receptors, while demonstrating no direct effect on Gq. We also evaluated the ability of FR900359, also known as UBO-QIC, to directly inhibit Gq activation. FR900359 inhibited spontaneous Gαq nucleotide exchange, while having little effect on Gαsβγ, Gαiβγ, or Gα12/13βγ heterotrimer activity. Both P4pal-10 and FR900359 inhibited Gq-mediated intracellular signaling and primary human airway smooth muscle growth, whereas only FR900359 effectively interdicted agonist-promoted airway contraction in human precision cut lung slices. These studies serve as a proof of concept that the broad-based inhibition of Gq activation may be a useful therapeutic approach to treat multiple common pathologies of airway disease.